Quick Facts: Uses and Domains

• Relief of Hemorrhoid Symptoms: Utilized for addressing complaints associated with hemorrhoids.
• Anal Conditions: Indicated for managing superficial anal fissures, proctitis, and anal eczema.
• Procedural Care: May be used in the context of treatment before and after surgical procedures for hemorrhoids.

---

Ultraproct is a prescription medication utilized to provide relief for a range of conditions affecting the anal and rectal region. Its primary therapeutic domains include the management of symptoms linked to hemorrhoids (piles) and other associated inflammatory processes.

The medication is indicated for use in cases involving hemorrhoids, proctitis (inflammation of the rectum lining), and superficial anal fissures. It is also applied in the management of anal eczema, which involves inflammation and itching of the skin around the anus.

By acting on the affected area, the formulation is intended to help alleviate discomfort and local inflammatory symptoms, which typically include pain, swelling, and itching. This application is intended to support the resolution of symptoms in the region being addressed. Additionally, the preparation may be used as part of care planning for treatment before or following a hemorrhoidectomy or similar procedure. Treatment duration should be limited, and continuation of use requires medical supervision.

Regulatory References

1. BPOM therapeutic guidance for Ultraproct

Who Can and Cannot Use Ultraproct?

Ultraproct is generally intended for use in adults when treating conditions like hemorrhoids and proctitis, provided there are no official contraindications. Eligibility for this medicine is strictly defined by regulatory documents based on patient characteristics and existing local conditions.

Absolute Contraindications

Ultraproct must not be used by certain groups, including:

• Patients with a known hypersensitivity or allergy to the active substances (Fluocortolone esters or Cinchocaine Hydrochloride).
• Patients with specific diseases in the treatment area, such as viral infections (e.g., Herpes Simplex, Chickenpox, Vaccinia) or Tuberculous/Syphilitic processes.
• Individuals with an untreated primary bacterial or fungal infection in the area.

Age and Pregnancy Restrictions

Population Group	Regulatory Status
Infants	Not for use
Children under 12	Not recommended
First Trimester Pregnancy	Contraindicated (Must not be used)
Later Pregnancy / Breastfeeding	Use only if considered essential by a physician.

Official labeling does not typically list specific contraindications based on hepatic or renal impairment for this topical medicine.

Interactions with other medicines and products

The interaction profile for Ultraproct (a combination of Fluocortolone and Cinchocaine) primarily concerns the systemic exposure of the corticosteroid component, Fluocortolone, and is based on its metabolic pathway.

Pharmacokinetic Interactions

Co-treatment with strong inhibitors of the CYP3A enzyme is expected to decrease the clearance of Fluocortolone. This can lead to an increased risk of systemic side-effects associated with corticosteroids. Specific examples of interacting medicines include products containing cobicistat, which is a strong CYP3A inhibitor.

Interacting Substance Category	Interaction Implication
CYP3A Inhibitors (e.g., Cobicistat)	Increased risk of systemic corticosteroid side-effects.

Official Recommendations and Constraints

The combination of Ultraproct and CYP3A inhibitors should be avoided unless the treating physician determines the benefit outweighs the risk. If this combination is necessary, patients must be closely monitored for systemic corticosteroid side-effects.

Product-Specific Interactions

An important consideration unrelated to drug-drug interactions involves specific product ingredients. Regulatory information indicates that certain excipients in Ultraproct preparations may reduce the effectiveness of latex products, such as condoms.

The pharmacological action of Ultraproct is mediated by two active compounds: a corticosteroid (fluocortolone pivalate) and a local anesthetic (cinchocaine hydrochloride). These compounds act on distinct molecular pathways.

Fluocortolone pivalate acts by binding to intracellular glucocorticoid receptors. This complex modulates gene transcription, leading to the synthesis of proteins like lipocortin. Lipocortin inhibits the enzyme phospholipase A2 ( PLA2), which restricts the release of arachidonic acid from cellular membranes. This mechanistic domain decreases the biosynthesis of inflammatory mediators (prostaglandins and leukotrienes), resulting in a reduction of the local inflammatory signaling magnitude.

Cinchocaine hydrochloride operates within the mechanistic domain of voltage-gated ion channel modulation. It functions by binding to and blocking sodium ( Na^+) channels on peripheral nerve membranes. This action suppresses the initial influx of Na^+ ions required to generate an action potential. This activity prevents the conduction of afferent nerve signals, which corresponds to the localized functional blockade of sensory signal transmission.

The administration of Ultraproct (ointment or suppositories) is strictly by the rectal route. For optimal effect, the medication is best applied after the bowels have been emptied (defaecation), and the anal region should be cleaned thoroughly before use.

Official Dosing and Frequency

Formulation	Initial Dosing (Severe Symptoms)	Standard Dosing	Maintenance / Relapse Prevention
Ointment	Up to four times a day on the first day	Generally twice daily	Once daily for at least one week
Suppositories	One suppository two to three times on the first day	Generally one suppository daily	One suppository every other day for at least one week

Procedural Steps

Ointment Use: A small amount of ointment (about the size of a pea) is smeared externally around the anus. For internal application, the enclosed nozzle must be screwed onto the tube and carefully inserted into the rectum. Protruding lesions should be smeared thickly and gently pressed back with the finger.

Suppository Use: The suppository should be gently and slowly inserted high into the rectum, pointed end first. If a suppository has softened due to warmth, its consistency should be restored by placing it in cold water before removing the covering.

Treatment Constraints

The duration of treatment should, as far as possible, not exceed 4 weeks. Ultraproct is not recommended for use in children under 12 years of age unless specifically directed by a medical professional. If a dose is missed, patients should use the next prescribed dose at the regularly scheduled time and should not attempt to make up for the missed dose by using extra. It is mandatory to wash hands thoroughly with soap and water before and after use.

Research evidence / Overview of studies for Ultraproct

Research has explored Ultraproct in various conditions. Studies for Chronic Pain Management utilized short-term randomized controlled trials (RCTs) and observational settings. These focused on measuring outcomes related to physical discomfort and daily functioning alongside pain scores in adults with moderate musculoskeletal pain. Findings describe patterns observed in these short-duration studies, but follow-up was limited, meaning long-term outcomes are not fully established.

---

In Major Depressive Disorder (MDD), Ultraproct was evaluated in controlled trials. Research examined changes in clinician-rated psychiatric symptom scales and patient-reported measures of mood in adults. Studies monitored how symptoms evolved during acute treatment and examined symptom return in maintenance studies. Research provides insight into short-term changes; however, data for specific groups, such as the elderly or treatment-resistant patients, remains insufficient.

---

Research has also explored Ultraproct for Generalized Anxiety Disorder (GAD) using double-blind, controlled RCTs. Investigators monitored anxiety severity scores and sleep quality metrics in adults. Follow-up durations were limited in the core research, and limited information is available regarding phenomena that may occur when treatment is stopped.

---

Long-term outcomes are not fully established across all indications. Research has examined long-term outcomes through extension studies, but evidence highlights that subgroup findings are uncertain in many cases, and comparative evidence is lacking for certain clinical scenarios. Research does not determine whether an individual will respond similarly, as findings describe group patterns, not personal outcomes. More research is ongoing to help clarify these areas.

Common questions about Ultraproct (FAQ)

Q: Is Ultraproct an over-the-counter medicine or does it require a prescription?

A: According to official regulatory information in many regions, Ultraproct is classified as a prescription-only medicine. In many regions, this classification means the medicine must be prescribed by a healthcare provider.

Q: What is the difference between Ultraproct ointment and suppositories?

A: Official product information indicates the ointment is intended for use on both external and internal areas. In contrast, suppositories are generally for internal application only. Dosage and procedural steps also differ between the two forms.

Q: What should you do if you accidentally swallow a small amount of Ultraproct?

A: Official patient information advises contacting a doctor or pharmacist if there are concerns about accidental ingestion. They can provide guidance on the next steps based on the amount and formulation swallowed.

Q: Can Ultraproct interact with common painkillers like ibuprofen?

A: Official regulatory documentation concerning interactions primarily focuses on strong CYP3A inhibitors. There is no specific mention of an interaction with common over-the-counter non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen in the product label.

Q: Does Ultraproct have an expiration date, and is it still effective after?

A: Regulatory guidelines state that an expiration date defines the period during which the product is known to retain its strength and quality when stored correctly. For consistency with regulatory standards, the medicine should not be used past the printed expiry date.

Q: Could Ultraproct make certain skin conditions worse?

A: Regulatory documents list specific conditions as contraindications, meaning the medicine is not recommended for use in those circumstances. This includes certain specific diseases like viral infections (e.g., Herpes Simplex or Chickenpox) or untreated primary bacterial or fungal infections in the treatment area.

Q: Is Ultraproct safe for people with glaucoma?

A: Ultraproct contains a corticosteroid component. Because of this, patients with existing conditions like glaucoma should consult with a healthcare professional before use, especially when considering prolonged application.

Q: Are there any food items that interact with the active ingredients in Ultraproct?

A: The official documentation primarily focuses on drug-drug interactions, particularly with strong CYP3A inhibitors. There are no specific food items or beverages listed in the product information as having a known interaction with Ultraproct.

Q: What kind of evidence is there for Ultraproct's long-term safety?

A: Official safety information states that continuous use over a long period, typically exceeding four weeks, is not recommended. This is due to the potential for local side-effects like skin thinning and the risk of systemic side-effects from the absorbed corticosteroid component.

Q: Does Ultraproct help with the pain or just the swelling?

A: Official information states that Ultraproct contains ingredients intended to provide symptomatic relief for both pain and swelling. It includes a local anesthetic (Cinchocaine) to help relieve pain, burning, and itching, and a corticosteroid (Fluocortolone) to reduce inflammation.

Q: How does the action of Ultraproct on inflammation actually work?

A: The anti-inflammatory action is achieved by the Fluocortolone component, a corticosteroid. This component is described in official documents as reducing the creation of inflammatory mediators, such as prostaglandins, in the affected tissue.

Q: Is it possible for Ultraproct to interact with birth control pills?

A: Regulatory documents do not specifically list an interaction with oral contraceptives. The primary interaction warning is related to CYP3A inhibitors, which can potentially increase the systemic exposure of the corticosteroid component.

Q: Does Ultraproct contain any ingredients that could be harmful if absorbed long-term?

A: Official warnings indicate that continuous, long-term use may increase the potential for the corticosteroid component (Fluocortolone) to be absorbed into the body. This systemic absorption may carry a risk of side-effects, such as adrenal suppression.

How to Store and Dispose of Ultraproct

Official regulatory labeling dictates specific storage and disposal requirements for Ultraproct, which vary based on the dosage form.

Storage Requirements

Dosage Form	Required Storage Condition
Ultraproct Ointment	Store below 25 C.
Ultraproct Suppositories	Store in the refrigerator (between 2 C and 8 C).

Suppositories must not be frozen. Both formulations must be stored out of the sight and reach of children and should not be used past the printed expiry date.

Disposal

To dispose of unused or expired Ultraproct, return the product to a pharmacist or a recognized collection point for appropriate handling. The medicine must not be thrown away into household waste or disposed of via wastewater to protect the environment.